Emerging biological drugs for the treatment of patients with metastatic HER2+ gastroesophageal adenocarcinomas.

Rogers JE, Horak A, Kroll A, Ajani JA

Open source

DOI
10.1080/14728214.2026.2705211
Published
2026 Sep
Container
Expert opinion on emerging drugs
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14728214.2026.2705211,
  title = {Emerging biological drugs for the treatment of patients with metastatic HER2+ gastroesophageal adenocarcinomas.},
  author = {Rogers JE and Horak A and Kroll A and Ajani JA},
  year = {2026},
  journal = {Expert opinion on emerging drugs},
  doi = {10.1080/14728214.2026.2705211},
  url = {https://doi.org/10.1080/14728214.2026.2705211}
}

RIS

TY  - JOUR
TI  - Emerging biological drugs for the treatment of patients with metastatic HER2+ gastroesophageal adenocarcinomas.
AU  - Rogers JE
AU  - Horak A
AU  - Kroll A
AU  - Ajani JA
PY  - 2026
JO  - Expert opinion on emerging drugs
DO  - 10.1080/14728214.2026.2705211
UR  - https://doi.org/10.1080/14728214.2026.2705211
ER  - 

APA

JE, R., A, H., A, K., & JA, A. (2026). Emerging biological drugs for the treatment of patients with metastatic HER2+ gastroesophageal adenocarcinomas.. Expert opinion on emerging drugs. https://doi.org/10.1080/14728214.2026.2705211

Source records